Search Results

Business

David Bruning Named Chief Executive Officer of StageBio

StageBio is pleased to announce the appointment of David Bruning as Chief Executive Officer.

February 12, 2024

·

3 min read

Business

StageBio Announces Opening of New Facility in Greater Boston Area

StageBio, a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving services for both preclinical and clinical research, has opened a new facility close to the biotechnology and medical research centers of Cambridge and Boston

August 13, 2020

·

2 min read

Business

StageBio Looks to Expand Its Life Sciences Footprint with New Massachusetts Facility

A new 10,000 square foot facility in Marlborough, MA will allow StageBio to offer their expanded histopathology expertise and grow the company’s reach across the greater Boston region.

September 1, 2020

·

3 min read

·

Alex Keown

Deals

StageBio and Alizée Pathology Merge

StageBio has merged with Alizée Pathology to form the leading provider of specialized histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device and contract research industries

November 7, 2019

·

3 min read

Deals

StageBio and Tox Path Specialists Merge

StageBio has merged with Tox Path Specialists, LLC (TPS) to create the leading provider of research and preclinical histology, pathology, specialized neuropathology, and archiving services for the biopharmaceutical, medical device and contract research industries.

April 11, 2019

·

3 min read

Deals

StageBio Expands Its Global Presence With Acquisition of TPL Path Labs

Company extends preclinical and clinical histopathology/molecular pathology solutions to researchers on both sides of the Atlantic

October 21, 2020

·

4 min read

Deals

HSRL and VPS Announce New Brand: StageBio

The new brand and identity encapsulates the commitment of expansion and growth following the merger of Histo-Scientific Research Laboratories with Vet Path Services and investment from Ampersand Capital Partners

March 12, 2019

·

2 min read

Drug Development

Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial

Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment.

April 29, 2024

·

4 min read

Genetown

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology makes immune cells more effective in killing tumor cells, today announced the results of several studies of its INTASYL™ compounds.

November 10, 2022

·

9 min read

Business

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights.

August 16, 2021

·

9 min read